A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C genotype 1b infection and a high viral load

Intervirology

Volumn 47, Issue 2, 2004, Pages 102-107

  Izumi, Namiki ^a   Asahina, Yasuhiro ^a   Kurosaki, Masayuki ^a   Uchihara, Masakatsu ^a   Nishimura, Yuki ^a   Inoue, Kazunari ^a   Ueda, Ken ^a   Tsuchiya, Kaoru ^a   Hamano, Kousei ^a   Itakura, Jun ^a   Miyake, Shozo ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Genotype 1; HCV dynamics; PEG interferon; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS VIRUS; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

HEPATITIS C VIRUS;

EID: 3042636460     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077833     Document Type: Article

References (23)

1. 1WHO: Hepatitis C: Global prevalence. Wkly Epidemiol Rec 1997;72:341-344.
2. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
3. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S: Pegylated interferon-α-2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556-567.
4. Talpaz M, O'Brien S, Crotes J, Kurzrock R, Gutterman J, Keating MJ, McCredie KB, Freireich EJ: Phase 1 study of polyethylene glycol (PEG) interferon alpha-2b (Intron A) in CML patients (abstract). Blood 1998;92(suppl):251A.
5. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
6. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK, Hepatitis Interventional Therapy Group: A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b in combination with ribabirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Results of a randomized trial. Lancet 2001;35:958-965.
8. Lau JYN, Tam RC, Liand TJ, Hong Z: Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002;35:1002-1009.
9. Jen JF, Glue P, Gupta S: Population pharmacokinetics and phamacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000;22:555-565.
10. Neumann AU, Lam NP, Dahari H: Hepatitis C viral dynamics in vivo and the antiviral efficacy on interferon-alpha therapy. Science 1998;282:1167-1169.
11. Takeuchi T, Katsume A, Tanaka T, Abe A, Inoue K, Tsukiyama-Kohara K, Kawaguchi R, Tanaka S, Kohara M: Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 1999;116:636-642.
12. Asahina Y, Izumi N, Uchihara M, Noguchi O, Tsuchiya K, Hamano K, Itakura J, Miyake S, Sakai T: A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology 2001;34:377-384.
13. Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C, Murray-Lyon I, Lypnyj D, Flannery B, Walters K, Dusheiko GM: Ribavirin and interferon alfa-2b in chronic hepatitis C: Assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol 1998;45:563-570.
14. Tsubota A, Akuta N, Suzuki F, Suzuki Y, Someya T, Kobayashi M, Arase Y, Saitoh S, Ikeda K, Kumada H: Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus genotype 1b and high pretreatment viral load. Intervirology 2002;45:33-42.
15. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ: Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000;182:28-35.
16. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK: Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996;23:366-371.
17. Yasui K, Okanoue T, Murakami Y, Itoh Y, Minami M, Sakamoto S, Sakamoto M, Nishioji K: Dynamics of hepatitis C viremia following interferon-alpha administration. J Infect Dis 1998;177:1475-1479.
18. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, Ding JW, Liu MF, Rotstein O, Phillips MJ, Levy G: Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160:3487-3493.
19. Tam RC, Pai B, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T: Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999;30:376-382.
20. Martin J, Navas S, Quiroga JA, Pardo M, Carreno V: Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 1998;10:635-644.
21. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW: Peginterferon alone or with ribavirin enhances HCV-specific CD4+ T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002;123:1070-1083.
22. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE: The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000;6:1375-1379.
23. Crotty S, Cameron CE, Andino R: RNA virus error catastrophe: Direct molecular test by using ribavirin. Proc Natl Acad Sci USA 2001;98:6895-6900.